# Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

> **NCT05239468** · PHASE2 · COMPLETED · sponsor: **Intercept Pharmaceuticals** · enrollment: 72 (actual)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** Bezafibrate 100 mg
- **DRUG:** Bezafibrate 200 mg
- **DRUG:** Obeticholic Acid 5 mg
- **DRUG:** Obeticholic Acid placebo
- **DRUG:** Bezafibrate Placebo

## Key facts

- **NCT ID:** NCT05239468
- **Lead sponsor:** Intercept Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-21
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05239468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05239468, "Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05239468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*